MX2015013091A - Metodos mejorados de uso para secretoglobinas humanas recombinantes. - Google Patents
Metodos mejorados de uso para secretoglobinas humanas recombinantes.Info
- Publication number
- MX2015013091A MX2015013091A MX2015013091A MX2015013091A MX2015013091A MX 2015013091 A MX2015013091 A MX 2015013091A MX 2015013091 A MX2015013091 A MX 2015013091A MX 2015013091 A MX2015013091 A MX 2015013091A MX 2015013091 A MX2015013091 A MX 2015013091A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- secretoglobins
- recombinant human
- improved methods
- scgb1a1
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 102000011274 Secretoglobin Human genes 0.000 title abstract 2
- 108050001520 Secretoglobin Proteins 0.000 title abstract 2
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 abstract 2
- 101000739178 Homo sapiens Secretoglobin family 3A member 2 Proteins 0.000 abstract 2
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 abstract 2
- 102100037268 Secretoglobin family 3A member 1 Human genes 0.000 abstract 2
- 102100037269 Secretoglobin family 3A member 2 Human genes 0.000 abstract 2
- 102100031083 Uteroglobin Human genes 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 2
- 230000000241 respiratory effect Effects 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005713 exacerbation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/843,289 US20140274915A1 (en) | 2013-03-15 | 2013-03-15 | Methods of Use for Recombinant Human Secretoglobins |
| PCT/US2014/030101 WO2014145357A2 (en) | 2013-03-15 | 2014-03-16 | Improved methods of use for recombinant human secretoglobins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015013091A true MX2015013091A (es) | 2016-10-07 |
Family
ID=51529893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013091A MX2015013091A (es) | 2013-03-15 | 2014-03-16 | Metodos mejorados de uso para secretoglobinas humanas recombinantes. |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20140274915A1 (enExample) |
| EP (1) | EP2968464B1 (enExample) |
| JP (1) | JP6513632B2 (enExample) |
| KR (1) | KR20160011621A (enExample) |
| CN (1) | CN105722524B (enExample) |
| AU (1) | AU2014233116A1 (enExample) |
| BR (1) | BR112015021265A2 (enExample) |
| CA (1) | CA2907395A1 (enExample) |
| ES (1) | ES2883933T3 (enExample) |
| IL (1) | IL241418A0 (enExample) |
| MX (1) | MX2015013091A (enExample) |
| RU (1) | RU2662665C2 (enExample) |
| SG (1) | SG11201507276UA (enExample) |
| UA (1) | UA118756C2 (enExample) |
| WO (1) | WO2014145357A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140274915A1 (en) * | 2013-03-15 | 2014-09-18 | Clarassance, Inc. | Methods of Use for Recombinant Human Secretoglobins |
| WO2016205430A1 (en) * | 2015-06-15 | 2016-12-22 | Therabron Therapeutics, Inc. | Recombinant human cc10 protein facilitates repair and protects against damage to the respiratory epithelium due to exposure to both cigarette and other smoke |
| WO2018178051A1 (en) * | 2017-03-28 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Scgb1a1 polymorphism for the prediction and therapy or prevention of primary graft dysfunction |
| WO2019143934A1 (en) | 2018-01-19 | 2019-07-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cancer activity of scbg3a2 and lps |
| JP2022509856A (ja) * | 2018-11-30 | 2022-01-24 | エーピーシー リサーチ アセッツ，エルエルシー | ヘパラン硫酸プロテオグリカンタンパク質との相互作用を介してグリコカリックスを保護するためのセクレトグロビンの組成物及び使用方法 |
| KR20200138684A (ko) * | 2020-11-17 | 2020-12-10 | 김유신 | 토양 파쇄기를 장착한 친환경 고온스팀 토양소독기 |
| WO2023212398A1 (en) * | 2022-04-29 | 2023-11-02 | Apc Research Assets Llc | Secretoglobins for suppression of antibody responses |
| CN119631983B (zh) * | 2024-12-30 | 2025-07-22 | 西南医科大学 | 一种心脏原发性肿瘤小鼠模型的构建方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040047857A1 (en) | 1997-05-28 | 2004-03-11 | Pilon Aprile L. | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
| US20030008816A1 (en) | 1997-05-28 | 2003-01-09 | Pilon Aprile L. | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
| US20060281681A1 (en) * | 1997-05-28 | 2006-12-14 | Pilon Aprile L | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease |
| AU5551299A (en) | 1998-08-13 | 2000-03-06 | Trustees Of The University Of Pennsylvania, The | Method of identifying proteins |
| US6953666B1 (en) | 1998-11-06 | 2005-10-11 | Emory University | Biomarkers for oxidative stress |
| WO2004101824A1 (ja) * | 2003-05-14 | 2004-11-25 | Shionogi & Co., Ltd. | 慢性閉塞性肺疾患の検出方法 |
| AU2004254600A1 (en) * | 2003-06-26 | 2005-01-13 | Lifesensors, Inc. | Methods and compositions for enhanced protein expression and purification |
| US7318936B2 (en) | 2003-11-14 | 2008-01-15 | Alza Corporation | Minimization of drug oxidation in drug irradiated excipients formulations |
| US20060275794A1 (en) * | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| JP2007059191A (ja) | 2005-08-24 | 2007-03-08 | Kazuo Kono | 照明器具駆動回路 |
| WO2008039941A2 (en) * | 2006-09-27 | 2008-04-03 | The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services | Scgb3a2 as a growth factor and anti-apoptotic agent |
| US20090004684A1 (en) | 2007-05-23 | 2009-01-01 | Claudia Susanne Maier | Compositions and Methods for Detection and Quantification of Protein Oxidation |
| EP2488205B1 (en) | 2009-10-15 | 2016-09-21 | Clarassance, Inc. | Recombinant human cc10 protein for treatment of influenza |
| RU2439569C1 (ru) * | 2010-11-12 | 2012-01-10 | Федеральное государственное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения и социального развития Российской Федерации | Способ прогнозирования бронхолегочной дисплазии у детей с врожденной пневмонией |
| US20140274915A1 (en) | 2013-03-15 | 2014-09-18 | Clarassance, Inc. | Methods of Use for Recombinant Human Secretoglobins |
-
2013
- 2013-03-15 US US13/843,289 patent/US20140274915A1/en not_active Abandoned
-
2014
- 2014-03-16 CN CN201480015596.0A patent/CN105722524B/zh not_active Expired - Fee Related
- 2014-03-16 AU AU2014233116A patent/AU2014233116A1/en not_active Abandoned
- 2014-03-16 EP EP14763146.9A patent/EP2968464B1/en active Active
- 2014-03-16 UA UAA201509797A patent/UA118756C2/uk unknown
- 2014-03-16 KR KR1020157029167A patent/KR20160011621A/ko not_active Ceased
- 2014-03-16 MX MX2015013091A patent/MX2015013091A/es active IP Right Grant
- 2014-03-16 CA CA2907395A patent/CA2907395A1/en not_active Abandoned
- 2014-03-16 RU RU2015144359A patent/RU2662665C2/ru active
- 2014-03-16 SG SG11201507276UA patent/SG11201507276UA/en unknown
- 2014-03-16 WO PCT/US2014/030101 patent/WO2014145357A2/en not_active Ceased
- 2014-03-16 ES ES14763146T patent/ES2883933T3/es active Active
- 2014-03-16 JP JP2016503332A patent/JP6513632B2/ja active Active
- 2014-03-16 BR BR112015021265A patent/BR112015021265A2/pt not_active IP Right Cessation
-
2015
- 2015-09-09 IL IL241418A patent/IL241418A0/en unknown
- 2015-10-12 US US14/880,908 patent/US9765127B2/en active Active
-
2017
- 2017-09-18 US US15/707,934 patent/US10556938B2/en active Active
-
2020
- 2020-02-07 US US16/785,221 patent/US11512121B2/en active Active
-
2022
- 2022-11-28 US US18/070,407 patent/US20240376162A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016520531A (ja) | 2016-07-14 |
| ES2883933T3 (es) | 2021-12-09 |
| UA118756C2 (uk) | 2019-03-11 |
| US20240376162A1 (en) | 2024-11-14 |
| EP2968464A2 (en) | 2016-01-20 |
| US10556938B2 (en) | 2020-02-11 |
| RU2662665C2 (ru) | 2018-07-26 |
| US9765127B2 (en) | 2017-09-19 |
| US20180244735A1 (en) | 2018-08-30 |
| CA2907395A1 (en) | 2014-09-18 |
| CN105722524B (zh) | 2020-02-21 |
| SG11201507276UA (en) | 2015-10-29 |
| IL241418A0 (en) | 2015-11-30 |
| EP2968464A4 (en) | 2016-11-09 |
| WO2014145357A2 (en) | 2014-09-18 |
| US20140274915A1 (en) | 2014-09-18 |
| US11512121B2 (en) | 2022-11-29 |
| KR20160011621A (ko) | 2016-02-01 |
| BR112015021265A2 (pt) | 2017-10-10 |
| US20200262878A1 (en) | 2020-08-20 |
| AU2014233116A1 (en) | 2015-09-24 |
| US20160159870A1 (en) | 2016-06-09 |
| RU2015144359A (ru) | 2017-04-25 |
| EP2968464B1 (en) | 2021-05-05 |
| WO2014145357A3 (en) | 2014-12-31 |
| CN105722524A (zh) | 2016-06-29 |
| JP6513632B2 (ja) | 2019-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015013091A (es) | Metodos mejorados de uso para secretoglobinas humanas recombinantes. | |
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| MX2021002713A (es) | Modulador del receptor de androgeno y usos de este. | |
| MX380273B (es) | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp. | |
| MX373851B (es) | Métodos de administración de tratamiento con pirfenidona. | |
| EP3141603A4 (en) | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective | |
| BR112015025955A2 (pt) | tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| BR112015022846A2 (pt) | uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo | |
| EP3019138A4 (en) | Guiding means for administering acupuncture and other healing procedures | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| TW201613599A (en) | Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease | |
| MX2020006075A (es) | Composiciones farmaceuticas de bendamustina. | |
| BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica | |
| PH12015500178A1 (en) | Injectable supersaturated acetaminophen solution for spinal administration | |
| PH12014000105A1 (en) | Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds | |
| IN2014DE00818A (enExample) | ||
| IN2013MU02732A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |